Business Development (5)

Challenge: A pharmaceutical company with a proprietary clinical trial technology made the strategic decision to diversify their development arm by acquiring and/or in-licensing pharmaceutical...

Challenge: A client developing a repurposed drug for use in male fertility asked Alacrita to conduct a valuation for the asset in the US and EU4+UK in support of impending deal negotiations. The...

Challenge: An east coast biotechnology company had reached non-binding terms with an overseas company for development and commercialization rights to a novel anti-cancer product with a...

Challenge: A well-capitalized US biotechnology company was considering entry into the CAR-T space through a license and research collaboration with a leading US university with a distinguished and...

Challenge: A mid-sized Japanese pharmaceutical company had made the strategic decision to expand their pipeline and geographical footprint by securing global development and commercialization rights...

Challenge: A private equity investor was considering a transaction involving a speciality pharma company dedicated to pediatric medicines. The target company had successfully launched a major product...

Challenge: A Chinese biotech company was evaluating a potential in-license product, a first-in-class agent for the treatment of ataxia and tremors in patients with Spinocerebellar Ataxia (SCA). The...

Challenge: An established Alacrita client building a business in the inhaled therapeutics sector asked us to carry out a technical and commercial due diligence of two development stage companies...

Challenge: A biotech company with an AI-approach to developing new TCRs for immunotherapy asked Alacrita to assist in preparations for the J.P. Morgan Healthcare conference.

Challenge: A contract development and manufacturing organization (CDMO) was in negotiations to acquire two manufacturing sites from other companies. Under normal circumstances, the client would have...

Challenge: For a mid-size European pharma company thinking of entering a new therapeutic area, we conducted ‘Triage’ level due diligence which focused only on publicly available information for three...

Challenge: A biotechnology startup had entered a major licensing deal with Big Pharma and was able to fund operations via the upfront payment rather than needing to raise a Series A. This introduced...